-
1
-
-
0037043655
-
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
-
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, . Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.
-
(2002)
N Engl J Med
, vol.347
, Issue.6
, pp. 408-415
-
-
Herbrecht, R.1
Denning, D.W.2
Patterson, T.F.3
Bennett, J.E.4
Greene, R.E.5
Oestmann, J.W.6
Kern, W.V.7
Marr, K.A.8
Ribaud, P.9
Lortholary, O.10
Sylvester, R.11
Rubin, R.H.12
Wingard, J.R.13
Stark, P.14
Durand, C.15
Caillot, D.16
Thiel, E.17
Chandrasekar, P.H.18
Hodges, M.R.19
Schlamm, H.T.20
Troke, P.F.21
de Pauw, B.22
more..
-
2
-
-
33746754115
-
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
-
Mikus G, Scho¨wel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006, 80(2):126-135.
-
(2006)
Clin Pharmacol Ther
, vol.80
, Issue.2
, pp. 126-135
-
-
Mikus, G.1
Scho¨wel, V.2
Drzewinska, M.3
Rengelshausen, J.4
Ding, R.5
Riedel, K.D.6
Burhenne, J.7
Weiss, J.8
Thomsen, T.9
Haefeli, W.E.10
-
3
-
-
84865423887
-
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring
-
Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012, 56(9):4793-4799.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.9
, pp. 4793-4799
-
-
Dolton, M.J.1
Ray, J.E.2
Chen, S.C.3
Ng, K.4
Pont, L.G.5
McLachlan, A.J.6
-
4
-
-
84859085055
-
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia
-
Aouri M, Decosterd LA, Buclin T, Hirschel B, Calmy A, Livio F. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS 2012, 26(6):776-778.
-
(2012)
AIDS
, vol.26
, Issue.6
, pp. 776-778
-
-
Aouri, M.1
Decosterd, L.A.2
Buclin, T.3
Hirschel, B.4
Calmy, A.5
Livio, F.6
-
5
-
-
79959400397
-
Pharmacogenomics of the triazole antifungal agent voriconazole
-
Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011, 12(6):861-872.
-
(2011)
Pharmacogenomics
, vol.12
, Issue.6
, pp. 861-872
-
-
Mikus, G.1
Scholz, I.M.2
Weiss, J.3
-
6
-
-
84869029614
-
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
-
Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol 2011,
-
(2011)
J Clin Pharmacol
-
-
Lee, S.1
Kim, B.H.2
Nam, W.S.3
Yoon, S.H.4
Cho, J.Y.5
Shin, S.G.6
Jang, I.J.7
Yu, K.S.8
-
7
-
-
78650070154
-
Clinical importance of the CYP2C19*17 variant allele for voriconazole
-
Dolton MJ, McLachlan AJ. Clinical importance of the CYP2C19*17 variant allele for voriconazole. Br J Clin Pharmacol 2011, 71(1):137-138.
-
(2011)
Br J Clin Pharmacol
, vol.71
, Issue.1
, pp. 137-138
-
-
Dolton, M.J.1
McLachlan, A.J.2
-
8
-
-
79960613122
-
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
-
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011, 90(2):328-332.
-
(2011)
Clin Pharmacol Ther
, vol.90
, Issue.2
, pp. 328-332
-
-
Scott, S.A.1
Sangkuhl, K.2
Gardner, E.E.3
Stein, C.M.4
Hulot, J.S.5
Johnson, J.A.6
Roden, D.M.7
Klein, T.E.8
Shuldiner, A.R.9
-
9
-
-
84855953171
-
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
-
Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 2012, 22(2):159-165.
-
(2012)
Pharmacogenet Genomics
, vol.22
, Issue.2
, pp. 159-165
-
-
Scott, S.A.1
Sangkuhl, K.2
Shuldiner, A.R.3
Hulot, J.S.4
Thorn, C.F.5
Altman, R.B.6
Klein, T.E.7
-
10
-
-
85027937843
-
Incorporation of Flurbiprofen in a 4-Drug Cytochrome P450 Phenotyping Cocktail
-
Bosilkovska M, Cle´ment M, Dayer P, Desmeules J, Daali Y. Incorporation of Flurbiprofen in a 4-Drug Cytochrome P450 Phenotyping Cocktail. Basic Clin Pharmacol Toxicol 2014,
-
(2014)
Basic Clin Pharmacol Toxicol
-
-
Bosilkovska, M.1
Cle´ment, M.2
Dayer, P.3
Desmeules, J.4
Daali, Y.5
-
11
-
-
84868014757
-
Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections
-
Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother 2012, 56(11):6001-6002.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.11
, pp. 6001-6002
-
-
Boyd, N.K.1
Zoellner, C.L.2
Swancutt, M.A.3
Bhavan, K.P.4
-
12
-
-
0344512407
-
Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole
-
Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003, 56(Suppl 1):51-55.
-
(2003)
Br J Clin Pharmacol
, vol.56
, pp. 51-55
-
-
Purkins, L.1
Wood, N.2
Kleinermans, D.3
Nichols, D.4
-
13
-
-
40549127134
-
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
-
Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008, 65(Suppl 1):27-37.
-
(2008)
Br J Clin Pharmacol
, vol.65
, pp. 27-37
-
-
Abel, S.1
Russell, D.2
Taylor-Worth, R.J.3
Ridgway, C.E.4
Muirhead, G.J.5
-
14
-
-
34948894967
-
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects
-
Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007, 51(10):3617-3626.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, Issue.10
, pp. 3617-3626
-
-
Liu, P.1
Foster, G.2
Gandelman, K.3
LaBadie, R.R.4
Allison, M.J.5
Gutierrez, M.J.6
Sharma, A.7
|